JAZZ - Jazz Pharma's Xywav late-stage study results published in peer reviewed journal

Jazz Pharmaceuticals (JAZZ) has announced the publication of Phase 3 study results of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness ((EDS)) in adults with narcolepsy. The results were published in SLEEP, the peer-reviewed, international journal of the Sleep Research Society.As recently announced, Xywav achieved the primary and key secondary endpoints in Phase 3 study, demonstrating highly statistically significant differences in median change in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores, compared to placebo.Xywav contains 92% less sodium per nightly dose than sodium oxybate, a current standard of care in this patient population as designated by the American Academy of Sleep Medicine Guidelines.

For further details see:

Jazz Pharma's Xywav late-stage study results published in peer reviewed journal